Develops oral small-molecule cancer drug candidates for people with cancers driven by RAS and phosphoinositide kinase alpha.
10-K for FY2025, filed Mar 5, 2026
8-K, filed Apr 23, 2026
On April 20, 2026, the Board of Directors (the “Board”) of BridgeBio Oncology Therapeutics, Inc. (the “Company”) approved the appointment…View ↗
Competes with AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer, Merck KGaA, Regeneron Pharmaceuticals, Sanofi Genzyme, and Roche
10-K for FY2025, filed Mar 5, 2026We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates…View ↗
Loading...